DTC
Deep Track Capital Portfolio holdings
AUM
$3.11B
This Quarter Return
-2.66%
1 Year Return
+13.6%
3 Year Return
+265.73%
5 Year Return
–
10 Year Return
–
AUM
$3.09B
AUM Growth
+$3.09B
(+16%)
Cap. Flow
+$741M
Cap. Flow
% of AUM
24.01%
Top 10 Holdings %
Top 10 Hldgs %
53.08%
Holding
78
New
16
Increased
25
Reduced
8
Closed
8
Top Buys
| 1 |
Protagonist Therapeutics
PTGX
|
$96.7M |
| 2 |
Ionis Pharmaceuticals
IONS
|
$79.4M |
| 3 |
Tarsus Pharmaceuticals
TARS
|
$76.2M |
| 4 |
Akero Therapeutics
AKRO
|
$69.6M |
| 5 |
BridgeBio Pharma
BBIO
|
$68.5M |
Top Sells
| 1 |
SWTX
SpringWorks Therapeutics
SWTX
|
$125M |
| 2 |
Harmony Biosciences
HRMY
|
$49.9M |
| 3 |
Neumora Therapeutics
NMRA
|
$42.4M |
| 4 |
Genmab
GMAB
|
$41.7M |
| 5 |
Guardant Health
GH
|
$41.6M |
Sector Composition
| 1 | Healthcare | 100% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Shares Change % | Capital Flow | |
|---|---|---|---|---|---|---|
|
ITCI
1
DELISTED
Intra-Cellular Therapies Inc.
ITCI
| $264M | 8.54% | 2,000,000 | – | – |
|
|
2
Guardant Health
GH
$8.41B
| $232M | 7.51% | 5,443,721 -975,845 | -15% | -$41.6M |
|
3
Dynavax Technologies
DVAX
$1.19B
| $231M | 7.47% | 17,791,486 | – | – |
|
4
Immunovant
IMVT
$2.56B
| $162M | 5.26% | 9,500,000 +3,500,000 | +58% | +$59.8M |
|
|
5
Protagonist Therapeutics
PTGX
$3.67B
| $145M | 4.7% | 3,000,000 +2,000,000 | +200% | +$96.7M |
|
|
6
Ionis Pharmaceuticals
IONS
$6.79B
| $138M | 4.46% | 4,564,207 +2,630,279 | +136% | +$79.4M |
|
|
7
Akero Therapeutics
AKRO
$3.74B
| $130M | 4.21% | 3,210,270 +1,720,270 | +115% | +$69.6M |
|
8
Cytokinetics
CYTK
$4.23B
| $124M | 4% | 3,073,853 +573,853 | +23% | +$23.1M |
|
9
Apellis Pharmaceuticals
APLS
$3.48B
| $109M | 3.54% | 5,000,000 +725,079 | +17% | +$15.9M |
|
10
Ocular Therapeutix
OCUL
$2.12B
| $105M | 3.39% | 14,294,420 +1,458,138 | +11% | +$10.7M |
|
|
11
BridgeBio Pharma
BBIO
$9.89B
| $96.8M | 3.13% | 2,800,000 +1,980,838 | +242% | +$68.5M |
|
|
12
Tarsus Pharmaceuticals
TARS
$2.47B
| $76.2M | 2.47% | +1,484,266 | New | +$76.2M |
|
13
Viridian Therapeutics
VRDN
$1.5B
| $72.5M | 2.35% | 5,380,449 +857,708 | +19% | +$11.6M |
|
14
Structure Therapeutics
GPCR
$1.11B
| $71M | 2.3% | 4,100,000 +1,300,000 | +46% | +$22.5M |
|
15
89bio
ETNB
$1.34B
| $67.7M | 2.19% | 9,316,333 +2,838,084 | +44% | +$20.6M |
|
16
Nurix Therapeutics
NRIX
$714M
| $65.3M | 2.12% | 5,500,000 +2,500,000 | +83% | +$29.7M |
|
17
Geron
GERN
$893M
| $60.7M | 1.97% | 38,176,251 +34,164,964 | +852% | +$54.3M |
|
18
Sarepta Therapeutics
SRPT
$1.78B
| $57.4M | 1.86% | +899,731 | New | +$57.4M |
|
19
Ultragenyx Pharmaceutical
RARE
$2.89B
| $48.9M | 1.58% | 1,350,000 +696,487 | +107% | +$25.2M |
|
20
ANI Pharmaceuticals
ANIP
$2.03B
| $46.9M | 1.52% | 700,000 +50,958 | +8% | +$3.41M |
|
21
Dianthus Therapeutics
DNTH
$759M
| $42.8M | 1.38% | +2,357,702 | New | +$42.8M |
|
22
Immunocore
IMCR
$1.62B
| $41.9M | 1.36% | 1,411,402 +892,026 | +172% | +$26.5M |
|
23
Celldex Therapeutics
CLDX
$1.47B
| $36.3M | 1.18% | 2,000,000 +459,868 | +30% | +$8.35M |
|
|
MAZE
24
Maze Therapeutics, Inc. Common Stock
MAZE
$635M
| $36M | 1.17% | +3,269,126 | New | +$36M |
|
25
Amgen
AMGN
$155B
| $35.2M | 1.14% | +113,035 | New | +$35.2M |
|